Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $42.35 in the prior trading day, Hims & Hers Health Inc (NYSE: HIMS) closed at $41.53, down -1.94%. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 14.18 million shares were traded. HIMS stock price reached its highest trading level at $42.14 during the session, while it also had its lowest trading level at $40.78.
Ratios:
Our goal is to gain a better understanding of HIMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 80.59. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65. TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 26 ’25 when Okupe Oluyemi sold 11,581 shares for $43.69 per share. The transaction valued at 505,968 led to the insider holds 116,806 shares of the business.
Boughton Soleil sold 2,571 shares of HIMS for $114,487 on Aug 25 ’25. The Chief Legal Officer now owns 150,450 shares after completing the transaction at $44.53 per share. On Aug 25 ’25, another insider, Boughton Soleil, who serves as the Officer of the company, bought 2,571 shares for $44.53 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 9386610688 and an Enterprise Value of 9286366208. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.98, and their Forward P/E ratio for the next fiscal year is 52.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 16.66. Its current Enterprise Value per Revenue stands at 4.612 whereas that against EBITDA is 57.984.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.14, which has changed by 1.8425736 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $13.47. The 50-Day Moving Average of the stock is -16.69%, while the 200-Day Moving Average is calculated to be 1.21%.
Shares Statistics:
The stock has traded on average 38.21M shares per day over the past 3-months and 21782500 shares per day over the last 10 days, according to various share statistics. A total of 217.38M shares are outstanding, with a floating share count of 202.66M. Insiders hold about 10.34% of the company’s shares, while institutions hold 77.81% stake in the company. Shares short for HIMS as of 1755216000 were 70218527 with a Short Ratio of 1.84, compared to 1752537600 on 65295727. Therefore, it implies a Short% of Shares Outstanding of 70218527 and a Short% of Float of 38.5.
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Hims & Hers Health Inc (HIMS) in the stock market.The consensus estimate for the next quarter is $0.26, with high estimates of $0.31 and low estimates of $0.17.
Analysts are recommending an EPS of between $1.24 and $0.78 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.77 and $0.99.
Revenue Estimates
11 analysts predict $579.33M in revenue for the current quarter. It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 11 analysts are estimating revenue of $631.31M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $592.7M.
A total of 13 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 12 analysts’ estimates, the company’s revenue will be $2.8B in the next fiscal year. The high estimate is $3B and the low estimate is $2.5B.
